Travere Therapeutics FY25 sales surged on Filspari, but the FDA FSGS label decision was delayed to April. Click here to read ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc. (NASDAQ: TVTX).

MIRM shares rise this week on strong preliminary 2025 sales, upbeat 2026 outlook, key pipeline goals and business updates.

Nvidia and Eli Lilly unveiled a co-innovation AI Lab for drug discovery efforts. Nvidia announced a strategic collaboration ...

Small caps and chips led the stock market this week. JPMorgan, Goldman Sachs, Delta Air Lines and Taiwan Semiconductor were ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The overall tally of drug approvals is down from 114 in 2024, with the EMA ascribing that record number to post-pandemic pent-up demand. However, the agency is expecting momentum to be maintained in ...

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...